Eli Lilly and

LLY · NYSE · USD

$1,142.85−0.61%−$7.00

Close · October 2, 2026

At a glance

Revenue growth: +44.70%; 2025 vs 2024
Net income growth: +94.90%; 2025 vs 2024
Net margin: 31.7%; 2024: 23.5%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total assets	112,476	78,715	64,006	49,490	48,806	46,633	39,286	43,908	44,981	38,806
Current assets	55,629	32,740	25,727	18,035	18,452	17,462	13,710	20,550	19,202	15,101
Cash and equivalents	7,268	3,268	2,819	2,067	3,819	3,657	2,338	7,321	6,536	4,582
Short-term investments	—	155	109	145	90.1	24.2	101	88.2	1,498	1,457
Receivables	20,116	12,939	11,093	8,302	8,113	6,888	5,523	5,696	5,235	4,732
Inventory	13,744	7,589	5,773	4,310	3,886	3,980	3,191	3,098	4,458	3,562
Net property, plant and equipment	25,935	18,152	13,938	10,144	8,985	8,682	7,873	7,996	8,827	8,253
Goodwill	5,898	5,770	4,940	4,073	3,892	3,767	3,679	1,367	4,370	3,973
Other intangible assets	6,521	6,166	6,907	7,207	7,692	7,450	6,618	1,068	4,029	4,358
Long-term investments	2,802	3,216	3,407	3,201	3,405	3,198	2,126	2,018	5,714	5,276
Current liabilities	35,228	28,376	27,293	17,138	15,053	12,482	11,775	11,888	14,536	10,987
Accounts payable	5,379	3,229	2,599	1,931	1,671	1,607	1,405	1,207	1,411	1,349
Long-term debt	40,868	28,527	18,425	14,872	15,387	16,785	13,844	9,241	9,977	8,368
Total debt	43,865	30,453	20,275	14,875	16,927	16,886	13,870	9,876	11,020	9,006
Total liabilities	85,941	64,443	53,143	38,714	39,651	40,808	36,587	32,999	33,313	24,725
Total equity (incl. minority)	26,535	14,272	10,864	10,775	9,155	5,825	2,699	10,909	11,668	14,081
Retained earnings	24,470	13,545	10,312	10,043	8,959	7,830	4,920	11,396	13,894	16,046
Minority interest	—	79.5	91.8	126	176	184	92.2	1,080	75.7	72.8